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Abstract
Background: The Na+/Cl--dependent serotonin (5-hydroxytryptamine, 5-HT) transporter (SERT)
is a critical element in neuronal 5-HT signaling, being responsible for the efficient elimination of 5-
HT after release. SERTs are not only targets for exogenous addictive and therapeutic agents but
also can be modulated by endogenous, receptor-linked signaling pathways. We have shown that
neuronal A3 adenosine receptor activation leads to enhanced presynaptic 5-HT transport in vitro
and an increased rate of SERT-mediated 5-HT clearance in vivo. SERT stimulation by A3 adenosine
receptors derives from an elevation of cGMP and subsequent activation of both cGMP-dependent
protein kinase (PKG) and p38 mitogen-activated protein kinase. PKG activators such as 8-Br-cGMP
are known to lead to transporter phosphorylation, though how this modification supports SERT
regulation is unclear.
Results: In this report, we explore the kinase isoform specificity underlying the rapid stimulation
of SERT activity by PKG activators. Using immortalized, rat serotonergic raphe neurons (RN46A)
previously shown to support 8-Br-cGMP stimulation of SERT surface trafficking, we document
expression of PKGI, and to a lower extent, PKGII. Quantitative analysis of staining profiles using
permeabilized or nonpermeabilized conditions reveals that SERT colocalizes with PKGI in both
intracellular and cell surface domains of RN46A cell bodies, and exhibits a more restricted,
intracellular pattern of colocalization in neuritic processes. In the same cells, SERT demonstrates a
lack of colocalization with PKGII in either intracellular or surface membranes. In keeping with the
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ability of the membrane permeant kinase inhibitor DT-2 to block 8-Br-cGMP stimulation of SERT,
we found that DT-2 treatment eliminated cGMP-dependent kinase activity in PKGI-
immunoreactive extracts resolved by liquid chromatography. Similarly, treatment of SERT-
transfected HeLa cells with small interfering RNAs targeting endogenous PKGI eliminated 8-Br-
cGMP-induced regulation of SERT activity. Co-immunoprecipitation studies show that, in
transporter/kinase co-transfected cells, PKGIα specifically associates with hSERT.
Conclusion: Our findings provide evidence of a physical and compartmentalized association
between SERT and PKGIα that supports rapid, 8-Br-cGMP-induced regulation of SERT. We discuss
a model wherein SERT-associated PKGIα supports sequentially the mobilization of intracellular
transporter-containing vesicles, leading to enhanced surface expression, and the production of
catalytic-modulatory SERT phosphorylation, leading to a maximal enhancement of 5-HT clearance
capacity.
Background
Signaling by the neurotransmitter serotonin (5-hydrox-
ytryptamine, 5-HT) plays a critical, modulatory role in
brain pathways supporting mood, appetite, sexual behav-
ior, and reward. The inactivation of synaptic 5-HT is
achieved largely through the actions of presynaptic serot-
onin transporters (SERT, SLC6A4). SERTs also participate
in presynaptic 5-HT recycling to sustain neuronal 5-HT
stores: this is most evident in studies with SERT KO mice
that display a 60–80% reduction in brain 5-HT level [1].
These mice also display profound changes in 5-HT recep-
tor coupling and a loss of psychostimulant (MDMA,
"ecstasy") sensitivity [1-5], underscoring the importance
of SERT for 5-HT signaling and drug response.
Increasing evidence indicates that SERT-mediated 5-HT
clearance is controlled by multiple regulatory pathways
that dictate both SERT plasma membrane expression and
catalytic activity (reviewed in [6]). By analogy with the
structure of the recently crystallized, SLC6 homolog Leu-
TAa [7], SERTs are modeled to possess twelve transmem-
brane domains [8] with intracellular amino and carboxy
termini. These latter domains possess multiple canonical
Ser/Thr phosphorylation sites and are known to interact
directly with other proteins, including Hic-5, neuronal
nitric oxide synthase (nNOS), as well as heteromeric
integrins that contain a β3 subunit [9-11]. Further specifi-
cation and localization of the key molecules involved in
SERT regulation, clarification of whether they form stable
or transient associations with SERT, and evaluation of
how loss of regulation contributes to SERT dysfunction
may offer important insights into 5-HT-linked brain dis-
orders such as depression, autism, and obsessive-compul-
sive disorder (OCD) [12-15]. In this regard, we and others
have shown that multiple human SERT coding variants
display compromised regulation through protein kinase
C (PKC)-, cGMP-dependent protein kinase (PKG)-, and
p38 mitogen-activated protein kinase (p38 MAPK)-linked
pathways [16-19]. Among these coding variants are
mutants found to associate with autism and OCD [20,21].
A detailed analysis of the signaling pathways that regulate
SERT may thus make important contributions to our
understanding of multiple neuropsychiatric disorders and
offer new strategies for intervention.
Our previous work has elucidated the actions of multiple
G-protein coupled receptors that can regulate SERT nega-
tively (e.g. α2 adrenergic receptors [22]) or positively (e.g.
A3 adenosine receptors (A3ARs, [23,24]). A3ARs enhance
SERT trafficking and 5-HT clearance capacity as a conse-
quence of elevations in intracellular Ca++ and cGMP and
PKG activation [23,24]. We have shown that PKG-
dependent regulation of SERT by A3ARs is present both in
cultured RBL-2H3 mast cells [23] and in serotonergic neu-
ronal terminals monitored ex vivo or in vivo [24]. Consist-
ent with these findings, SERTs are phosphorylated by
treatment of cells or neurons with the general PKG activa-
tors 8-pCPT-cGMP and 8-Br-cGMP [17,25]. Two genes
encoding homologous PKG proteins have been identified,
PKGI and PKGII (also identified as cGK1 and 2, [26]),
both of which can be stimulated by membrane-permeant
cGMP analogs. PKGI is a soluble, cytosolic protein that is
abundant in smooth muscle, platelets, and brain [27,28].
Mice lacking PKGI have profound smooth muscle deficits
that lead to eventual death [29]. These deficits can be res-
cued in constitutive PKGI KO mice by smooth muscle-
specific rescue using either of the two PKGI amino-termi-
nal splice variants PKGIα or PKGIβ [30]. PKGII is a myris-
toylated, membrane-associated protein that is most
abundant in intestine, brain, and kidney [31,32]. PKGII
knockout mice exhibit dwarfism and defects in intestinal
secretion [33]. Which of the two PKG genes participate in
SERT regulation, or whether both contribute, is presently
unknown though critical for further mechanistic studies
that pursue whole animal genetic or pharmacological
manipulations.
Neuroanatomical studies are lacking that document the
precise localization in brain of PKG isoforms in relation to
SERT expression, likely due to the insensitivity of availableMolecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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reagents for determining kinase localization in situ outside
of very prominent sites of expression, such as cell bodies
of the cerebellum (Steiner and Blakely, unpublished find-
ings). However, we have demonstrated that A3 agonist
stimulation of SERT in synaptosomes in vitro and in the
hippocampus in vivo can be antagonized by the peptide
DT-2, a membrane-permeant inhibitor proposed to block
selectively PKGI [24,34]. In the present work, we demon-
strate expression of DT-2 sensitive, cGMP-dependent
kinase activity that comigrates with PKGI immunoreactive
protein in RN46A cells, where we also document colocal-
ization of SERT with PKGI, but not PKGII, by quantitative
immunofluorescence approaches. SERT/PKGI colocaliza-
tion is most evident when labeling of the transporter is
achieved in permeabilized cells, consistent with a pre-
dominant role of PKGI in regulating of transporter vesic-
ular trafficking. Consistent with this idea, PKGI-targeted
siRNAs completely eliminate 8-Br-cGMP-triggered SERT
stimulation, regulation that arises from elevated trans-
porter surface expression. Co-immunoprecipitation stud-
ies reveal that SERT forms a stable complex with PKGI,
with a greater efficiency of association achieved with
PKGIα over PKGIβ. We discuss the impact of our findings
with respect to a model for how intracellular SERT/PKGI
associations support both trafficking-dependent and -
independent modes of SERT regulation.
Results
Expression and colocalization of PKGI with SERT in 
RN46A cells
To initiate studies of PKG gene products engaged in neu-
ronal SERT regulation, we explored the expression of PKG
isoforms in RN46A cells, a serotonergic cell line that we
have previously found to display 8-Br-cGMP-stimulated
SERT activity. Initially, we performed qualitatitive RT-PCR
analysis on total RN46A RNA using oligonucleotide prim-
ers specific for PKGIα, PKGβ and PKGII. Compared to rat
midbrain RNA, where we readily identified expression of
all three gene products, RN46A RNA only yielded ampli-
fication of PKGIα and PKGIβ (Fig. 1A). Next, we pursued
immunofluorescence studies of RN6A cells, where we
confirmed readily detectable expression of PKGI and SERT
(Fig. 1B–D) and low expression of PKGII (Fig 1E). Stain-
ing with PKGI or PKGII primary antibodies was elimi-
nated with preabsorption against their respective antigens
(Fig. 1B, middle panel; also see Additional File 1). Stain-
ing was also absent in cells treated with fluorescent sec-
ondary antibodies alone and in the case of PKGI, when
cells were not permeabilized (data not shown). For SERT
localization studies, RN46A cells were probed with a SERT
ectodomain antibody under two conditions. One set of
assays involved probing for SERT prior to permeabiliza-
tion (NP, Fig. 1), followed by permeabilization of cells to
detect cytoplasmic PKG. A second evaluation involved use
of both SERT and PKG antibodies under permeabilized
(P, Fig. 1) conditions. P cells displayed a broader cellular
pattern of SERT staining than nonpermeabilized cells
(compare Fig. 1B, left and right panels), consistent with
detection of a pool of surface SERTs in NP cells. Dual-
labeling experiments under these conditions revealed evi-
dence of significant colocalization of PKGI with SERT
under NP conditions, localized primarily to RN46A cell
bodies (Fig. 1C, right panel, closed arrowhead). In these
preparations, areas devoid of PKGI labeling, but positive
for SERT, were clearly evident at the tips of processes (Fig.
1C, right panel, open arrowhead). With P conditions,
PKGI/SERT colabeling was more extensive than under NP
conditions, filling both the cell soma as well as processes
(Fig. 1D, right panel). In keeping with a lack of detection
of PKGII in the RN46A cells, low signal for PKGII was evi-
dent by immunofluorescence (Fig. 1E, middle panel) and
was detected as a nuclear pattern surrounded by diffuse
cytoplasmic labeling. SERT/PKGII colocalization evalua-
tion in double labeling preparations (Fig. 1E, right panel)
was quite distinct from that observed with PKGI, and
showed no evidence for overlap in patterns of expression.
To assess PKG and SERT colocalization using quantitative
approaches, we calculated the Intensity Colocalization
Quotient (ICQ) under either NP or P conditions for both
cell bodies and processes. As described by Li and col-
leagues [35], ICQ values represent a measure of the extent
of correlation of intensity values in space for 2 separate
fluorophores, where values range between -0.5 and 0.5 for
negatively and positively correlated signals, respectively.
As shown in Fig. 2, PKGI/SERT ICQ values fall signifi-
cantly above 0 under some conditions, whereas PKGII/
SERT analyses yield no ICQ values different from 0 under
any condition, suggesting a random relationship of stain-
ing. For PKGI/SERT under NP conditions, significant colo-
calization is evident only in the cell body area. Under P
conditions, significant colocalization of PKGI/SERT is evi-
dent for both the cell soma and processes, in keeping with
the qualitative evaluations noted above. These findings
provide quantitative evidence of PKGI/SERT colocaliza-
tion (our PKGI antibody cannot distinguish PKGIα and β)
and reveal that PKGI/SERT complexes are largely intracel-
lular in distal processes.
DT-2 sensitive PKGI activity in RN46A cells
DT-2 is a membrane permeant peptide that was developed as
a PKGI inhibitor [34] and has been previously demonstrated
to eliminate SERT stimulation following A3AR stimulation
or exogenous 8-Br-cGMP treatments [24,36]. Prior studies of
kinase specificity in vitro using purified kinases, indicate a Ki
of 12.5 ± 3.0 nM for purified PKGI (either PKGIα or PKGIβ)
versus 75.5 ± 18 μM for PKA [34]. We extended these find-
ings to PKGII and PKCα, yielding Ki values of 9.10 ± 1.3 μM
and 26.6 ± 4.0 nM, respectively. Although DT-2 can inhibit
PKCα at concentrations comparable to PKGI inhibition,Molecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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Colocalization of SERT and PKGI in RN46A cells Figure 1
Colocalization of SERT and PKGI in RN46A cells. A) Total RNA from RN46A cells or rat midbrain was isolated and 
subjected to RT-PCR as described in Methods. Figure shows agarose gel analysis of cDNA products, revealing expression of 
PKGI but very little PKGII. B-E) Double immunocytochemical labeling of SERT, PKGI, and PKGII. RN46A cells were fixed, 
stained, and imaged by confocal microscopy as described in Methods. SERT staining was achieved with an ectodomain antibody 
(Advanced Targeting AB-N09). NP, nonpermeabilized. P, permeabilized by 0.2% NP40. NP/B, nonpermeabilized with antibody 
preabsorbtion by peptide (Advanced Targeting PR-03). DIC image is inset in B, middle, to demonstrate presence of cells. Inset 
image in D, right, shows staining in process. Closed arrows indicate perinuclear staining while open arrows indicate process 
staining. Scale bars represent 10 μm. Data are representative of at least three independent experiments.Molecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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PKC activation leads to SERT internalization rather than a
movement to the surface and an enhancement of 5-HT
uptake. Regardless, our findings add support to the conten-
tion that the DT-2 sensitivity of cGMP-dependent SERT reg-
ulation is evidence of PKGI versus PKGII involvement. To
explore this issue further in the RN46A model, we fraction-
ated RN46A cell lysates via DEAE-Sephacel chromatography,
testing fractions for levels of PKGI-immunoreactive protein
as well as levels of cGMP-dependent phosphorylation of the
heptapeptide substrate (RKRSRAE). In Fig. 3A, we display a
representative analysis, plotting both PKGI protein level and
kinase activity from fractions where significant cGMP-
dependent kinase activity was detected. Activity in our kinase
assays does not necessarily derive from PKG activity as other
kinases, notably PKA, can utilize cGMP for activation [37].
Thus, in Fig. 3B, we analyze the sensitivity of cGMP-stimu-
lated kinase activity to DT-2. The fractions bearing the most
significant level of PKGI protein (fractions 13–17; 93.9% of
total PKGI immunoreactivity) exhibited a significantly
greater degree of DT-2 sensitivity as compared to fractions
where PKGI immunoreactivity was low or absent (fractions
18–22; 6.1%). Indeed, in fractions 13–17, all of the cGMP-
stimulated kinase activity (Fig. 3B, dotted line) was elimi-
nated whereas we detected DT-2 insensitive kinase activity in
fractions 18–22. Together, these studies demonstrate the
presence of DT-2-sensitive PKGI in RN46A cells and support
the likelihood that DT-2 blockade of cGMP-dependent SERT
stimulation in intact cells arises from antagonism of PKGI.
PKGI is required for 8-Br-cGMP-mediated increases in 
SERT activity in transfected cells
We have shown that SERT activity can be stimulated by 8-
Br-cGMP in multiple heterologous expression systems,
including transfected HeLa cells [17,20,36]. These obser-
vations allowed us to implement transient transfection of
PKGI-directed siRNAs to assess whether evidence, inde-
pendent of DT-2, could be gathered that PKGI is essential
for 8-Br-cGMP triggered SERT stimulation. Mock or
siRNA-treated HeLa cells (60 hrs) were subjected to either
vehicle or 8-Br-cGMP treatment (100 μM, 10 min) fol-
lowed by [3H]5-HT transport assays (20 nM, 10 min), as
described in Methods. As shown in Fig. 4, PKGI siRNA
treatments had no significant effect on basal SERT activity
in either mock or siRNA transfections. Additionally,
mock-transfected cells demonstrated the previously docu-
mented stimulation of SERT activity following 8-Br-cGMP
treatment [17]. In contrast, cells treated with PKGI siRNA
exhibited no 8-Br-cGMP-induced SERT stimulation.
hSERT forms a stable association with PKGIα
Although our studies above implicate PKGI in SERT regu-
lation, they do not address whether PKGI/SERT interac-
tions are transient or stable, nor do they identify which
isoform of PKGI is most likely involved in SERT regula-
tion since our PKGI antibodies are not isoform specific. As
SERT protein levels were too low in RN46A cells to permit
co-immunoprecipitation of SERT/PKGI complexes, we
performed transient co-transfections of HEK-293 T cells
using His-tagged hSERT and HA-tagged PKGI isoforms.
HA-PKGI complexes were isolated via anti-HA beads fol-
lowed by immunoblotting of total and co-imminoprecip-
itated extracts using an antibody against SERT. Anti-HA
blots of total cell lysates demonstrated equivalent expres-
sion of HA-PKGIα and HA-PKGIβ (Fig. 5A, arrow). Anti-
SERT blots revealed equivalent expression of hSERT (Fig.
5B, arrow). We did note a broader, higher Mr smear of
SERT-immunoreactive species in lanes cotransfected with
either PKG isoform. The origin of this altered SERT migra-
tion is as yet unclear, but could reflect a capacity of either
isoform to trigger SERT phosphorylation or lead indirectly
to the stabilization of multimeric, detergent-resistant
SERT complexes. However, only anti-HA bead eluates of
PKGIα revealed the presence of hSERT (Fig. 5C). These
studies provide evidence that stable complexes of hSERT
with PKGI are formed in transporter/kinase transfected
cells and uncover an unexpected specificity for the PKGIα
isoform in this model.
Discussion
Increasingly, we appreciate that biogenic amine transport-
ers typified by SERT are under complex regulatory control
mediated by associated proteins and multiple signaling
pathways [9-11,17,18,22,23,25,36,38-50]. Understand-
ing the molecules and contingencies involved in SERT reg-
ulation is likely to enhance our abilities to manipulate
SERT for therapeutic ends, as well as expand our under-
standing as to how SERT dysregulation contributes to
mental illness [16,17,20,21]. Miller and Hoffman first
identified a cGMP-linked pathway promoting rapid
enhancement of SERT activity following adenosine recep-
Quantitative analysis of SERT/PKGI colocalization Figure 2
Quantitative analysis of SERT/PKGI colocalization. 
Cells were fixed and stained as shown representatively in Fig-
ure 1, and the Intensity Correlation Quotient was calculated 
for both cell bodies and processes under either nonpermea-
bilized (NP) or permeabilized (P) conditions, as described in 
Methods. Data represent mean values ± SEM from multiple 
cells in 4–6 fields, replicated in at least three experiments. 
Statistical analysis was conducted by one-sample t test. *, p < 
0.001.Molecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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tor activation [44]. Thus, 8-Br-cGMP treatments recapitu-
late the actions of nonselective adenosine receptor
agonists on RBL-2H3 cells (e.g. 5'-N-ethylcarboxamidoad-
enosine, NECA) and these authors hypothesized that
cGMP-stimulated protein kinases might direct phosphor-
ylation of SERT or a SERT-associated protein to trigger
increased SERT activity. We now understand that A3ARs
and/or 8-Br-cGMP treatments can increase SERT activity
in multiple contexts, including the rat raphe cell line
RN46A [36], transfected CHO and HeLa cells [17,18], rat
midbrain and cortical synaptosomes in vitro and the
mouse hippocampus in vivo [47]. In all cases, pharmaco-
logical inhibition of PKG blocks stimulation of SERT
activity. Furthermore, biochemical and surface expression
studies reveal that PKG activators lead to both SERT phos-
phorylation [17,18,47] and enhanced SERT insertion into
the plasma membrane [17,19,23], providing an opportu-
nity for steady-state increases in 5-HT uptake capacity.
SERT trafficking regulation leads to p38 MAPK activation
that we have shown shifts the transporter to a higher affin-
ity state for 5-HT recognition [36]. Progress has also been
achieved in identifying a number of SERT-interacting pro-
teins [9-11,43,49] whose associations can impact both
SERT trafficking and transport rates. In this report, we pro-
vide evidence that PKGIα is responsible for rapid, 8-Br-
cGMP-dependent, DT-2-sensitive SERT stimulation.
Moreover, we demonstrate that mammalian cells can
organize a stable association of PKGIα with SERT, an
interaction likely to support the enhanced surface traffick-
ing of the transporter evident after treatment of cells with
PKG activators.
In RN46A cells, we established using qualitative and
quantitative approaches that endogenous PKGI and SERT
colocalize. Although PKGII could not be detected by RT-
PCR, low levels of PKGII immunoreactivity were evident
via confocal-assisted immunofluorescence studies. How-
ever, no evidence for SERT/PKGII colocalization was evi-
dent. Interestingly, SERT/PKGI colocalization was
nonuniform, being most prominent in permeabilized
preparations and absent in the distal segments of nonper-
meabilized cells. One possible explanation for these find-
ings is that SERT recruits PKGI to vesicles as part of a
coordinated mechanism to achieve regulated plasma
membrane trafficking and that, in distal processes, SERT
moves to the plasma membrane after dissociation of
PKGI. Extensive studies to date in our lab have failed to
document consistent interactions between PKGI and
SERT (Steiner and Blakely, unpublished findings), indi-
cating a role for an intermediate in formation of SERT/
PKGIα complexes. This intermediate could result in a
SERT (or PKG) post-translational modification or repre-
sent a SERT-associated protein lacking under the condi-
tions of in vitro incubations of purified proteins.
Additional studies are clearly needed to elaborate the
manner by which transporter/kinase associations are
formed. Future studies should also explore dynamic fea-
tures of the SERT/PKGI association, such as whether these
interactions change upon vesicle membrane fusion and
localization of SERT to plasma membrane subdomains.
PKG activation has been found to alter actin dynamics
and vesicular trafficking [51,52] as well as promote phos-
phorylation of a single Thr (Thr276) on SERT whose
DT-2 sensitive, PKGI activity in RN46A cells Figure 3
DT-2 sensitive, PKGI activity in RN46A cells. A) DEAE 
chromatography and phosphorylation assays of RN46A cell 
extracts were performed as described in Methods. Chroma-
togram displays cGMP-dependent (background-subtracted) 
kinase activity and quantitative protein measurement. cGMP-
independent kinase activity was measured as 27.3% of total 
kinase activity. Representative immunoblot of fractions with 
detectable kinase activity is shown below chromatogram. B) 
Evaluation of DT-2 sensitivity in fractions containing detecta-
ble (13–17) or nondetectable (18–22) PKGI protein by 
immunoblot. Both fraction bins 13–17 and 18–22 displayed 
DT-2-sensitive kinase activity (***, p < 0.001; **, p < 0.01), 
with fractions overlaying PKGI protein being significantly 
more sensitive to DT-2 (***, p < 0.001). Dashed line repre-
sents cGMP-independent kinase activity equivalent to 27.3%. 
Data shown are from a single experiment, are representative 
of three independent experiments, and are presented as 
means ± SEM. Statistical significance was calculated via two-
way ANOVA, followed by Bonferroni's post-test.Molecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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mutation can eliminate SERT stimulation [47]. Whether
Thr276 is phosphorylated directly by PKG, or possibly by
p38 MAPK, which PKG is known to activate [23,36,53], is
unknown. Since Thr276 is positioned within a short intra-
cellular loop connecting transmembrane domains pro-
posed to control 5-HT exit from the transporter [18,54], it
seems most likely that this site has relevance for catalytic
modulation, which we have shown is governed by p38
MAPK [23,36]. PKGI might then contribute to mobiliza-
tion of SERT vesicles not by phosphorylation of SERT, but
by phosphorylation of SERT vesicle tethering proteins.
However, it is also possible that additional phosphoryla-
tion sites targeted by PKGI may exist; these could support
transporter trafficking but be too transient to be captured
by standard biochemical methods. In addition to the
PKGIα associations we have defined, SERT associates with
the phosphatase PP2A [43]. The specific sites in SERT that
bind, or are dephosphorylated by PP2A, are not known,
but a polymorphism (Gly56Ala) within the hSERT amino
terminus leads to constitutive phosphorylation that can-
not be further elevated by 8-Br-cGMP. Moreover, the
Gly56Ala is a catalytically activated variant [17,19] that
also displays diminished sensitivity to the PP2A specific
inhibitor fostriecin [19]. Thus, it is possible that the SERT/
PKGIα associations documented here are mutually exclu-
sive with, or are modulated by SERT/PP2A interactions
and that these two enzymes govern phosphorylation sites
linked to SERT trafficking, as well as catalytic modulation.
Interestingly, p38 MAPK is known to phosphorylate and
activate PP2A [55], providing a path by which PKGI acti-
vation could lead to both p38 MAPK-dependent trans-
porter catalytic activation and efficient
dephosphorylation of trafficking regulatory SERT sites. A
mirror image of this idea related to SERT inactivation and
internalization has been proposed involving PKC and
PP2A by our lab [40,43] and the work of Ramamoorthy's
group [41]. Future studies that elucidate the sites targeted
by PP2A and PKC should greatly clarify these ideas. Since
OCD and autism-associated SERT variants appear to
impact PKG, p38 MAPK and PP2A-dependent transporter
regulation [18], this effort may also have significant
impact on our understanding of the origins of 5-HT linked
brain disorders.
We have recently proposed by analogy to the classical pic-
ture of insulin-dependent glucose transporter regulation
[56] that two modes of SERT trafficking to the plasma
membrane exist: one, a finite capacity, regulated pathway
overseen by PKG, p38 MAPK, PP2A and PKC, and a sec-
ond, constitutive pathway that is relatively insensitive to
these proteins but which can be more greatly populated
by heterologous overexpression. RN46A cells endog-
enously express a low level of SERT and display substan-
tial elevations (≥ 200%) in SERT activity following 8-Br-
cGMP treatment or p38 MAPK stimulation [36]. High-
level heterologous expression of SERT in transfected cells,
in our hands, leads to SERT proteins that demonstrate
greatly reduced, and in some cases, no cGMP-dependent
regulation. Due to this characteristic, we routinely con-
strain SERT expression in transfected cells where SERT reg-
ulation is being assessed, including the HeLa model we
have used in this study. Our goal is to approach the low
level of SERT expression observed in RN46A and RBL-2H3
cells. Unfortunately, such low expression levels make bio-
chemical studies, such as SERT/PKGI co-immunoprecipi-
tation experiments, extremely challenging, if not
impossible. Although we have utilized the higher express-
ing HEK-293T model for our co-immunoprecipitation
studies, our goal here was not to parallel functional stud-
ies, but rather to determine whether a portion of PKGI can
assemble in a SERT complex and whether PKGI isoform
specificity is evident. Additionally, we expect the pool of
PKGI that associates with SERT to be small, and likely dif-
ferentially localized, compared to the total PKGI pool.
This possibility likely explains why we do not observe ICQ
values for SERT and PKGI approaching 0.5, the theoretical
maximum, even in permeabilized cells. Our blots of
Treatment of transfected HeLa cells with PKGI siRNA pre- vents 8-Br-cGMP-induced SERT stimulation Figure 4
Treatment of transfected HeLa cells with PKGI 
siRNA prevents 8-Br-cGMP-induced SERT stimula-
tion. Cells were transfected with hSERT and siRNA directed 
against human PKGI and assayed for 8-Br-cGMP stimulation 
of SERT activity as described in Methods. Upon 8-Br-cGMP 
stimulation, cells expressing hSERT (closed bar) demonstrate 
elevated 5-HT transport activity (147 ± 3.56%) absent from 
cells treated with PKGI siRNA (dotted bar, 96.4 ± 6.96%). 
Cells treated with siRNA in the absence of 8-Br-cGMP 
(checkered bar) show no change in 5-HT uptake (94.5 ± 
1.88%) from control (open bar, 100 ± 0.010%). Each assay 
was repeated three times. Values are means ± SEM. ***, p < 
0.001 versus control, calculated via one-way ANOVA fol-
lowed by Tukey's post-test.Molecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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siRNA-treated HeLa extracts demonstrate only a modest
reduction in total PKGI level [see Additional file 2] despite
full elimination of 8-Br-cGMP triggered SERT stimulation.
We also observed a full elimination of p38 MAPK-
dependent regulation of SERT after only a modest reduc-
tion in p38α MAPK level by p38α MAPK-targeted siRNA
treatment [36]. Since siRNAs are cotransfected with hSERT
to evaluate transporter regulation, we thought it impor-
tant to determine whether the full inhibition of regulation
could be due to full suppression of kinase expression,
though limited to the small percentage of cells transfected.
Indeed, when we determined the percentage of cells trans-
fected with siRNA using toxic siRNAs [see Additional file
2], we found a good match to the percent reduction in
PKGI protein (~15% in both cases).
Conclusion
We provide evidence that native SERT and PKGI are coex-
pressed in rat serotonergic RN46A cells where the two pro-
teins colocalize, particularly when intracellular
transporter pools are visualized in situ using permeabi-
lized cells. In these cells, we corroborate the utility of the
membrane-permeant peptide inhibitor DT-2 to eliminate
cGMP-stimulated kinase activity, sensitivity that co-
migrates with immunoreactive PKGI following ion
exchange chromatography. Using PKGI siRNA, we estab-
lish a critical role for endogenous PKGI in 8-Br-cGMP trig-
gered SERT regulation. We demonstrate that stable SERT/
PKGIα complexes can be isolated from kinase/transporter
co-transfected cells, revealing an unexpected isoform spe-
cificity that will propel future studies to evaluate how the
alternatively spliced amino-terminal sequences that dis-
tinguish between PKGIα and β support PKGIα associa-
tions. Our studies thus illuminate a key facet of the
molecular network that underlies rapid regulation of
SERT via cell signaling pathways and compel further
investigation of the mechanisms by which PKGIα/SERT
associations are modulated by antidepressants, drugs of
abuse, and disease-associated SERT mutations.
Methods
Reagents
Most chemicals were purchased from Sigma-Aldrich (St.
Louis, MO). Culture medium (Dulbecco's modified
Eagle's medium and Ham's F-12) was prepared by the
Vanderbilt Media Core using Invitrogen (Invitrogen Cor-
poration, Carlsbad, CA) reagents. Trypsin-EDTA,
glutamine, and penicillin/streptomycin were also pur-
chased from Invitrogen. Fetal bovine serum was obtained
from Atlanta Biologicals (Norcross, GA). Anti-HA High
Affinity Matrix beads and rat anti-HA monoclonal anti-
body were purchased from Roche (Basel, Switzerland).
H8 hydrochloride was obtained from Cayman Chemical
(Ann Arbor, MI). 5-hydroxy [3H]tryptamine trifluoroace-
tate ([3H]5-HT, 76 Ci/mmol) was purchased from Amer-
sham Biosciences Inc. (Piscataway, NJ). Rabbit polyclonal
anti-PKGI antibodies were a generous gift from Dr. Robert
Feil (University of Tübingen, Tübingen, Germany) or were
purchased from Assay Design, Inc. (Ann Arbor, MI). Rab-
bit polyclonal antibody directed against PKGII was kindly
provided by Dr. Hugo De Jonge (Erasmus University, The
Netherlands). Mouse SERT monoclonal antibody was
from Advanced Targeting Systems (San Diego, CA).
Cell culture and transfection
RN46A cells (a generous gift from Dr. Scott Whittemore,
University of Louisville, Louisville, KY) were maintained
in DMEM/F-12 (1:1 in volume) containing 250 mg/L
G418, 10% FBS, 2 m M L-glutamine, 0.1 U/mL penicillin-
0.11 g/mL streptomycin. HEK-293 T cells and HeLa cells
were cultured in DMEM, 10% FBS, 2 m M L-glutamine,
0.1 U/mL penicillin-0.11 g/mL streptomycin. For co-
hSERT forms a stable association with PKGIα Figure 5
hSERT forms a stable association with PKGIα. hSERT and HA-PKGIα or HA-PKGIβ were coexpressed in HEK-293 T 
cells and coimmunoprecipitations were performed as described in Methods. Total cell extracts were blotted for A) HA to 
reveal PKG expression or B) SERT. C) Co-immunoprecipations of SERT and PKG using anti-HA for immunoprecipitations and 
anti-SERT for blotting. Experiment shown was replicated in four independent experiments with similar results.Molecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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expression studies, HEK-293 T cells were plated at a den-
sity of 100,000 cells/mL in individual wells of 6-well
plates one day before transfection. Transfections were per-
formed with TransIt®-LT1 (Mirus Bio Corporation, Madi-
son, WI) and 500 ng of each cDNA, in accordance with
manufacturer's instructions. For the siRNA studies, HeLa
cells were plated at a density of 10,000 cells/mL in indi-
vidual wells of a 24-well plate. Transfections were per-
formed with Lipofectamine™ 2000 (Invitrogen), 25 ng
pcDNA3-hSERT, and 100 n M siRNAs. For the siRNA stud-
ies, pcDNA3-hSERT and ON-TARGETplus SMARTpool
human PRKG1 siRNAs (Thermo Fisher Scientific, Pitts-
burgh, PA) were used for transfections. To evaluate siRNA
transfection efficiency, Allstars Hs Cell Death Control siR-
NAs (Qiagen, Valencia, CA) were transfected as described
for PKG siRNAs as described by the manufacturer and
dying/dead cells counted as a proportion of the total
number of cells transfected by phase microsocopy.
Plasmid constructs
The pcDNA3-His-hSERT construct was generated from
previously described pcDNA3-hSERT [39] by adding a
[His]6-Gly epitope sequence after the ATG start site using
the QuikChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA). pcDNA3-HA-PKGIα and pcDNA3-HA-
PKGIβ were kindly provided by Dr. Bo Cen (Columbia
University, New York, NY).
RT-PCR Studies
Total RNA from adult male, Sprague-Dawley rat midbrain
and from RN46As was isolated using 5 Prime PerfectPure
RNA kits (Fisher Scientific, Pittsburgh, PA) as described in
the manufacturer's protocol. 1 μg of RNA was subjected to
reverse transcription followed by PCR (RT-PCR) using the
TITANIUM™ One-Step RT-PCR Kit (Clontech Laborato-
ries, Inc., Mountain View, CA) and PKGIα (forward-5'
GGTACATACAATCCACAATCTC 3', reverse-5' CCTCTC-
CTCTCCTTCCTTTTAG 3'), PKGIβ(forward-5' GGTACAT-
ACAATCCACAATCTC 3', reverse-5'
AATCTGCACACTGAAACTCTCG 3') and PKGII (forward-
5' GATGTTCACCGCAAGACCT 3', reverse-5' CGATG-
TAACTGCCCTGTTGATA 3') specific oligonucleotide
primers (Invitrogen Corporation, Carlsbad, CA). Reaction
products were resolved by 2% agarose gel electrophoresis
and sequenced using dideoxy terminator sequencing
(Vanderbilt University Medical Center DNA Sequencing
Core).
Immunostaining
The immunofluorescence protocol was adapted from pre-
vious work [57]. Briefly, 1–2 days before fixation, RN46A
cells were seeded onto circular poly-D-lysine-coated cov-
erslips in 24-well plates. Cells were fixed with 4% parafor-
maldehyde for 30 min., followed by either
permeabilization with 0.2% NP40 or application of pri-
mary antibodies overnight at 4°C without detergent
(nonpermeabilized conditions). Treatment with second-
ary antibodies conjugated to fluorophores Cy2 or Cy5 for
1 hr was followed by mounting of coverslips to charged
slides. Indirect immunofluorescence images were cap-
tured using an LSM510 confocal microscope (Vanderbilt
University Medical Center Cell Imaging Shared Resource
supported by National Institutes of Health grants
CA68485, DK20593, DK58404, HD15052, DK59637 and
EY08126). Images were quantified using the Integration
Colocalization Analysis section of WCIF Image J http://
www.uhnresearch.ca/facilities/wcif/imagej/. Intensity
Correlation Quotient (ICQ) values are presented and
were taken as evidence for dependent staining or colocal-
ization when the ICQ value falls between 0 and + 0.5.
Independent staining or lack of colocalization was indi-
cated when ICQ values were not different from 0 or were
between 0 and -0.5. Data were analyzed by one-sample t-
test comparing means versus a value of 0.
Kinase inhibition assays using DT-2
Kinetic assays (Ki, IC-50) were performed as previously
described [34,58] with purified recombinant kinases and
multiple concentrations of DT-2 (YGRKKRRQRRRPP-
LRKKKKKH). Recombinant PKG Iα, PKG Iβ, PKA Iα (cat-
alytic subunit) and PKGII were expressed from insect cell
cultures using the Bacmid baculovirus expression system
(Gibco/Invitrogen) and purified to apparent homogene-
ity as described recently [34]. Recombinant PKCα
(human) was obtained from Calbiochem. All enzymes
were assayed using saturating concentrations of the pep-
tide TQAKRKKSLAMA as substrate. PKG isoforms were
activated with 1 μM cGMP, PKA was stimulated with 1 μM
cAMP, and PKC was activated using 50 μg/μL phospholi-
pids and 100 ng/mL 12-O-Tetradecanoylphorbol-13-ace-
tate.
Fractionation and activity assays
Approximately 500 million RN46A cells were homoge-
nized in ice-cold 10 mM potassium phosphate pH 6.8, 1
mM EDTA, and 25 mM β-mercaptoethanol (KPEM) and
centrifuged at 10,000 × g for 20 min. at 4°C. The superna-
tant was applied to a pre-equilibrated 0.9 × 8 cm DEAE-
Sephacel column and the column was washed with KPEM
with 20 mM NaCl. A linear gradient (20 mM to 280 mM
NaCl) was next run on the column and 30-drop fractions
were collected. As previously described [59], kinase assays
to determine PKG activity in each fraction were conducted
in the presence and absence of 10 μM cGMP (a PKG acti-
vator) and 136 μg/mL heptapeptide substrate (RKRSRAE)
as the PKG substrate. The cAMP-dependent protein kinase
(PKA) inhibitor PKI-tide (5–24) was also included in the
assay in order to block PKA activity. Activity was expressed
as picomoles of [32P] incorporated per min per mL of sam-
ple.Molecular Brain 2009, 2:26 http://www.molecularbrain.com/content/2/1/26
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Co-immunoprecipitations and immunoblotting
Two days post-transfection with his-hSERT and HA-PKGI
plasmids, HEK-293 T cells were detergent-extracted with
1% TRITON-X-100 and prepared for immunoprecipita-
tion, as previously described [43]. Briefly, protein concen-
trations of lysates were determined with a bicinchoninic
acid assay kit (Pierce, Rockford, IL), using bovine serum
albumin as a standard. 50–100 μg total protein was
immunoprecipitated with anti-HA High Affinity beads
(Roche) for 1 hr and eluted with Laemmli sample buffer.
Samples were subjected to SDS polyacrylamide gel elec-
trophoresis and electroblotted to polyvinylidene difluo-
ride membrane (Amersham), followed by incubation
with primary antibodies. Blots were thoroughly washed
with PBS containing 0.5% Tween-20 and developed with
enhanced chemiluminescence (Amersham) with multiple
exposures captured to ensure nonsaturation conditions.
Transport assays
60 hrs after transfection with pcDNA3-hSERT and siRNAs,
HeLa cells were subjected to 8-Br-cGMP treatment and 5-
HT transport assays as previously described [17]. Briefly,
transfected cells were treated with 100 μM 8-Br-cGMP for
10 min., then incubated with 20 n M [3H]5-HT for 10
min. After thorough washing with Krebs-Ringers-Hepes,
pH 7.4, cells were solubilized in MicroScint 20 (Perk-
inElmer, Waltham, MA) and [3H]5-HT accumulation was
quantified using a TopCount plate scintillation counter
(Perkin Elmer). Specific 5-HT uptake was determined by
subtracting the amount of [3H]5-HT taken up by non-
transfected cells.
Statistical analyses
All data were derived from experiments replicated a mini-
mum of three times. Values are expressed as mean ± SEM.
All Statistical analyses were completed in GraphPad Prism
(GraphPad, San Diego, CA). In Fig. 2, one-sample Stu-
dent's t tests were performed by comparing mean values
to 0, and a value of p < 0.05 was taken as statistically sig-
nificant. Analysis by one-way or two-way ANOVA was
used followed by post-hoc testing (Bonferroni or Tukey)
for Fig. 3 and 4, and a value of p < 0.05 was accepted as
statistically significant. In Additional file 2, Analysis via a
Repeated Measures One-Way ANOVA was utilized fol-
lowed by Bonferroni post-tests, and a value of p < 0.05 was
accepted as statistically significant.
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